###begin article-title 0
###xml 53 58 <span type="species:ncbi:9606">Human</span>
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
###end article-title 0
###begin p 1
currency Current address: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
###end p 1
###begin p 2
###xml 0 20 0 20 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 2
###begin p 3
###xml 0 21 0 21 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Author Contributions:</bold>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
Author Contributions: AP, KG, SY, VR, MS, and NK designed the study. KG, JC, TJR, YY, CB, IH, VR, and NK performed experiments. AP, KG, JC, YY, SY, IH, VR, MS, and NK analyzed the data. AP, KG, MS, and NK enrolled patients. AP, KG, MS, and NK contributed to writing the paper.
###end p 3
###begin article-title 4
Role of Osteopontin in Idiopathic Pulmonary Fibrosis
###end article-title 4
###begin title 5
Background
###end title 5
###begin p 6
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disorder characterized by fibroproliferation and excessive accumulation of extracellular matrix in the lung.
###end p 6
###begin title 7
Methods and Findings
###end title 7
###begin p 8
###xml 44 55 44 55 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 734 735 730 731 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 739 740 732 733 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 842 843 831 832 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 847 848 833 834 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 357 362 <span type="species:ncbi:9606">human</span>
###xml 1071 1076 <span type="species:ncbi:9606">human</span>
Using oligonucleotide arrays, we identified osteopontin as one of the genes that significantly distinguishes IPF from normal lungs. Osteopontin was localized to alveolar epithelial cells in IPF lungs and was also significantly elevated in bronchoalveolar lavage from IPF patients. To study the fibrosis-relevant effects of osteopontin we stimulated primary human lung fibroblasts and alveolar epithelial cells (A549) with recombinant osteopontin. Osteopontin induced a significant increase of migration and proliferation in both fibroblasts and epithelial cells. Epithelial growth was inhibited by the pentapeptide Gly-Arg-Gly-Asp-Ser (GRGDS) and antibody to CD44, while fibroproliferation was inhibited by GRGDS and antibody to alphavbeta3 integrin. Fibroblast and epithelial cell migration were inhibited by GRGDS, anti-CD44, and anti-alphavbeta3. In fibroblasts, osteopontin up-regulated tissue inhibitor of metalloprotease-1 and type I collagen, and down-regulated matrix metalloprotease-1 (MMP-1) expression, while in A549 cells it caused up-regulation of MMP-7. In human IPF lungs, osteopontin colocalized with MMP-7 in alveolar epithelial cells, and application of weakest link statistical models to microarray data suggested a significant interaction between osteopontin and MMP-7.
###end p 8
###begin title 9
Conclusions
###end title 9
###begin p 10
Our results provide a potential mechanism by which osteopontin secreted from the alveolar epithelium may exert a profibrotic effect in IPF lungs and highlight osteopontin as a potential target for therapeutic intervention in this incurable disease.
###end p 10
###begin p 11
Osteopontin may have a critical role in the pathogenesis of idiopathic pulmonary fibrosis, and be a target for therapeutic intervention in this disease.
###end p 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 266 267 266 267 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b01">1</xref>
###xml 268 269 268 269 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b02">2</xref>
###xml 381 382 381 382 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b02">2</xref>
###xml 383 384 383 384 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b03">3</xref>
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia of unknown etiology characterized by alveolar epithelial cell injury/activation, fibroblast proliferation, and exaggerated accumulation of extracellular matrix in the lung parenchyma [1,2]. The disease is usually progressive and largely unresponsive to corticosteroid and immunosuppressive therapy [2,3].
###end p 13
###begin p 14
###xml 242 243 242 243 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b04">4</xref>
###xml 387 388 387 388 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b01">1</xref>
###xml 389 390 389 390 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b05">5</xref>
###xml 729 730 729 730 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b01">1</xref>
###xml 731 732 731 732 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b04">4</xref>
###xml 733 734 733 734 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b07">7</xref>
###xml 695 701 <span type="species:ncbi:9606">humans</span>
A distinctive morphological feature of IPF is the development of fibroblastic/myofibroblastic foci, represented by widely scattered, small aggregates of subepithelial mesenchymal cells immersed within a myxoid-appearing extracellular matrix [4]. These fibroblastic/myofibroblastic foci represent areas of active fibrogenesis and play a crucial role in the progressive fibrotic response [1,5]. These sites are characterized by inappropriate re-epithelialization and impaired extracellular matrix remodeling. Although significant advances have been made in the characterization of the clinical and morphological features of this disease, the molecular mechanisms that underlie IPF pathogenesis in humans are still largely unknown [1,4-7].
###end p 14
###begin p 15
###xml 184 185 184 185 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b08">8</xref>
###xml 292 293 288 289 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 297 298 290 291 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 346 347 339 340 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b09">9</xref>
###xml 348 350 341 343 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b10">10</xref>
###xml 510 512 503 505 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b11">11</xref>
###xml 513 515 506 508 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b12">12</xref>
###xml 666 668 659 661 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b11">11</xref>
###xml 669 671 662 664 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b12">12</xref>
Osteopontin (also termed secreted phosphoprotein 1) is a phosphorylated acidic glycoprotein that contains an Arg-Gly-Asp motif that binds to the integrin family of adhesion molecules [8]. It functions as a cell adhesion and migration molecule that can bind to several ligands, including alphavbeta3 integrin, some CD44 isoforms, and fibronectin [9,10]. Osteopontin has been implicated in a number of physiological and pathological processes including bone resorption, malignant transformation, and metastasis [11,12]. It is also considered a key cytokine regulating inflammation, cellular immune response, and tissue repair, with a unique effect on T cell function [11,12].
###end p 15
###begin p 16
###xml 252 254 252 254 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b13">13</xref>
###xml 255 257 255 257 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b14">14</xref>
###xml 382 384 382 384 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b15">15</xref>
###xml 417 428 417 428 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 655 657 652 654 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b16">16</xref>
###xml 774 776 771 773 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b11">11</xref>
###xml 777 779 774 776 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b17">17</xref>
###xml 780 782 777 779 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b18">18</xref>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
Using oligonucleotide microarrays we previously demonstrated that osteopontin is highly up-regulated in bleomycin-induced lung fibrosis in mice, and we reported similar results in a preliminary report involving five IPF lungs and four control samples [13,14]. Interestingly, osteopontin seems to have a profibrotic effect in the development of bleomycin-induced pulmonary fibrosis [15]. After bleomycin instillation, osteopontin-null mice developed reduced lung fibrosis characterized by dilated distal air spaces with decreased active transforming growth factor-beta 1 (TGF-beta1) and reduced type I collagen expression compared with wild-type controls [16]. The mechanisms by which osteopontin, a cytokine with primarily TH1 effects (i.e., antifibrotic) on T lymphocytes [11,17,18], may cause profibrotic effects are not fully understood.
###end p 16
###begin p 17
###xml 275 303 275 303 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">matrix metalloprotease (MMP)</italic>
###xml 193 198 <span type="species:ncbi:9606">human</span>
In this study, we applied microarrays to analyze gene expression patterns in a larger cohort of IPF lungs (13 IPF samples and 11 controls), and we analyzed the direct effects of osteopontin on human lung fibroblasts, alveolar epithelial cell migration and proliferation, and matrix metalloprotease (MMP) gene expression in vitro.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
Study Population
###end title 19
###begin p 20
###xml 83 94 83 94 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sd001">Protocol S1</xref>
###xml 172 183 172 183 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sd002">Protocol S2</xref>
###xml 856 857 856 857 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b04">4</xref>
###xml 963 964 963 964 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b07">7</xref>
###xml 1250 1257 1250 1257 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020251-t001">Table 1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
Patients from the National Institute of Respiratory Diseases, Mexico City, Mexico (Protocol S1), and the University of Pittsburgh, Pittsburgh, Pennsylvania, United States (Protocol S2), were included in this study. The protocol was approved by both Institutions, and written informed consent was obtained where required. Samples for oligonucleotide microarray were obtained from the tissue bank of the Department of Pathology at the University of Pittsburgh. The use of archived tissue has been approved by the local Institutional review board. Diagnosis of IPF was supported by history, physical examination, pulmonary function studies, chest HRCT, and bronchoalveolar lavage (BAL) findings, and was corroborated by open lung biopsy. The morphologic diagnosis of IPF was based on typical microscopic findings consistent with usual interstitial pneumonia [4]. The patients fulfilled the criteria of the American Thoracic Society and European Respiratory Society [7]. BAL samples were obtained at first consult as part of the initial diagnostic work-up. None of the patients had been treated with corticosteroids or immunosuppressive drugs at the time of BAL. Demographic data, pulmonary function data, and BAL differential cell counts are provide in Table 1.
###end p 20
###begin p 21
###xml 494 502 <span type="species:ncbi:9606">patients</span>
Levels of osteopontin in BAL fluids were evaluated in ten healthy individuals (two current smokers, two former smokers, and six that had never smoked). All had normal chest X-rays and spirometries. Likewise, histologically normal lung tissues obtained at necropsy from six nonsmoking adult individuals who had died of causes unrelated to lung diseases were utilized for immunohistochemistry. For oligonucleotide microarrays, control samples included normal histology lung samples resected from patients with lung cancer obtained from the Pittsburgh Tissue Bank (Pittsburgh, Pennsylvania, United States).
###end p 21
###begin title 22
Oligonucleotide Microarrays
###end title 22
###begin p 23
###xml 574 576 574 576 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b11">11</xref>
###xml 1618 1620 1618 1620 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b19">19</xref>
###xml 1644 1646 1644 1646 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b20">20</xref>
###xml 1647 1649 1647 1649 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b21">21</xref>
###xml 1736 1737 1736 1737 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
Surgical remnants of biopsies or lungs explanted from patients with IPF that underwent pulmonary transplant were the sources of 13 IPF samples. Lung samples resected from patients with lung cancer, obtained from the tissue bank of the Department of Pathology at the University of Pittsburgh, were the sources of 11 normal samples. None of these samples had been included in our previous study. Total RNA was extracted and used as a template to generate double-stranded cDNA and biotin-labeled cRNA, as recommended by the manufacturer of the arrays and previously described [11]. Fragmented cRNA was hybridized to Codelink Uniset I slides. After hybridization, arrays were washed and stained with streptavidin-AlexaFluor 647. The arrays were scanned using a Genepix 4000B microarray scanner. Images were analyzed using Codelink expression II analysis suite. They were visually inspected for defects and quality control parameters as recommended by the manufacturer. Data files were imported into a microarray database and linked with updated gene annotations using SOURCE () and then median scaled. Based on our previous experience, all expression levels below 0.01 were brought to 0.01. Statistical analysis was performed using Scoregene gene expression package (, and data visualization was performed using Genexpress () and Spotfire Decision Site 8.0 (Spotfire, Goteborg, Sweden). The complete set of gene array data has been deposited in the Gene Expression Omnibus database with GEO serial accession number GSE2052 () according to MIAME guidelines. The general approach to analysis was previously described by us [19]. Weakest link models [20,21] were fitted using the Weaklink package for the R statistical software system (). The p-value was obtained from fitting a logistic regression model with a single independent variable that is the minimum of the percentiles for the expression levels for the two genes. A Bonferroni correction was applied for multiple testing.
###end p 23
###begin title 24
Bronchoalveolar Lavage
###end title 24
###begin p 25
###xml 233 234 233 234 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
BAL was performed through flexible fiberoptic bronchoscopy under local anesthesia. Briefly, 300 ml of normal saline was instilled in 50-ml aliquots, with an average recovery of 60%-70%. The recovered BAL fluid was centrifuged at 250 g for 10 min at 4 degreesC. The cell pellet was resuspended in 1 ml of PBS and an aliquot was used to evaluate the total number of cells. Other aliquots were fixed in carbowax, stained with hematoxylin and eosin, and used for differential cell count. Supernatants were kept at -70 degreesC until use.
###end p 25
###begin title 26
ELISA
###end title 26
###begin p 27
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Quantification of osteopontin was performed in BAL fluid samples from 18 IPF patients and 10 healthy individual controls, by using a commercial sensitive and specific ELISA following the instructions of the manufacturer (Calbiochem, La Jolla, California, United States).
###end p 27
###begin title 28
Immunohistochemistry
###end title 28
###begin p 29
###xml 75 76 75 76 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 77 78 77 78 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 581 582 575 576 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 583 584 577 578 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 608 610 602 604 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b15">15</xref>
###xml 611 613 605 607 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b19">19</xref>
###xml 192 198 <span type="species:ncbi:9986">Rabbit</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 383 394 <span type="species:ncbi:3704">horseradish</span>
Tissue sections were deparaffinized, rehydrated, and then blocked with 3% H2O2 in methanol for 30 min, then antigen was retrieved with citrate buffer (10 mM, pH 6.0) for 5 min in a microwave. Rabbit polyclonal antibody to human osteopontin (2 ng/ml; Calbiochem) was applied and samples were incubated at 4 degreesC overnight. A secondary biotinylated anti-immunoglobulin followed by horseradish peroxidase-conjugated streptavidin (BioGenex, San Ramon, California, United States) was used according to manufacturer's instructions. AEC (BioGenex) in acetate buffer containing 0.05% H2O2 was used as substrate [15,19]. The sections were counterstained with hematoxylin. The primary antibody was replaced by non-immune serum for negative control slides.
###end p 29
###begin title 30
Two-Color Immunofluorescence Analysis
###end title 30
###begin p 31
###xml 337 343 <span type="species:ncbi:9986">rabbit</span>
###xml 538 543 <span type="species:ncbi:10090">mouse</span>
###xml 813 818 <span type="species:ncbi:9940">sheep</span>
###xml 824 830 <span type="species:ncbi:9986">rabbit</span>
###xml 853 857 <span type="species:ncbi:9925">goat</span>
###xml 863 868 <span type="species:ncbi:10090">mouse</span>
A standard two-stage double-immunofluorescence labeling technique was used. Briefly, frozen sections were washed in PBS (0.01 M [pH 7.4]) for 5 min and then fixed in cold acetone for 10 min, twice. Tissues were incubated in blocking buffer (1% BSA, 5% normal serum, 0.05% NP-40, in PBS) for 30 min. The slides were then incubated with a rabbit antibody to osteopontin (1:100; Abcam, Cambridge, Massachusetts, United States) for 1 h at room temperature and washed in PBST (0.05% Tween-20 in 0.01 M PBS [pH 7.4]) for 10 min, three times. A mouse anti-MMP-7 monoclonal antibody (1:1,000; Chemicon International, Temecula, California, United States) was added and the slides were incubated for an additional 1 h at room temperature. After three 10-min washes in PBST, slides were incubated with secondary antibodies (sheep anti-rabbit IgG-Cy3, 1:1,000; and goat anti-mouse IgG-FITC, 1:1,000; Sigma-Aldrich, St. Louis, Missouri, United States) for 30 min. Slides were then washed in the same buffer and mounted with antifade medium (containing DAPI to stain cell nuclei).
###end p 31
###begin title 32
Cell Culture
###end title 32
###begin p 33
###xml 77 79 77 79 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b22">22</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
Primary human normal lung fibroblasts were obtained as previously described [22], and the A549 cell line was obtained from ATCC (Rockville, Maryland, United States). 
###end p 33
###begin title 34
Growth Rate Assay
###end title 34
###begin p 35
###xml 98 99 98 99 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 110 111 110 111 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 295 296 289 290 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 652 654 645 647 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b19">19</xref>
###xml 805 806 794 795 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 810 811 796 797 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 917 922 <span type="species:ncbi:9606">human</span>
###xml 1079 1084 <span type="species:ncbi:9606">human</span>
Lung fibroblasts or A549 cells were seeded in 96-well culture plates at a cell density of 7.5 x 103 and 5 x 103 cells/well respectively, and incubated in Ham's F-12 and DMEM media, respectively (GIBCO-BRL, Grand Island, New York, United States), supplemented with 10% FBS at 37 degreesC in 5% CO2 and 95% air. After 12 h, the medium was replaced by medium with 0.1% FBS alone or 0.1% FBS plus increasing concentrations of osteopontin (0.4, 1, and 2 mug/ml) and the cells were maintained in culture for another 48 h. Cell growth was determined using the cell proliferation reagent WST-1 (Boehringer Mannheim, Mannheim, Germany) as previously described [19]. All assays were performed in triplicate. In parallel experiments, fibroblasts and A549 cells were pretreated for 25 min with antibody to human alphavbeta3 integrin (10 mug/ml; Chemicon), the pentapeptide Gly-Arg-Gly-Asp-Ser (GRGDS; Calbiochem), or antibody to human CD44 (NeoMarkers, Fremont, California, United States), and then osteopontin was added (2 mug/ml). Additionally, A549 cells were pretreated with antibody to human epidermal growth factor receptor (EGFR; 10 mug/ml; Chemicon).
###end p 35
###begin title 36
Cell Migration Assay
###end title 36
###begin p 37
###xml 376 377 363 364 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 835 836 815 816 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 519 524 <span type="species:ncbi:9606">human</span>
Migration of fibroblasts and A549 cells was assayed using commercially available 24-well collagen-coated Boyden chambers (Chemicon) with an 8-mum pore size. Briefly, a semi confluent (approximately80%) monolayer of lung fibroblasts or A549 cells was harvested with trypsin-EDTA, centrifuged, and resuspended in Ham's F-12 medium containing 5% BSA. The cell suspensions (3 x 105 cells/well) were added to the upper chamber. The lower chamber contained 0.3 ml of medium with 5% BSA alone or with 10 mug/ml of recombinant human osteopontin (Calbiochem). PDGF (8 ng/ml) and epidermal growth factor (EGF; 50 ng/ml) were used as positive controls for fibroblasts and for A549 cells, respectively. Additional BSA-coated chambers were used as blanks for each sample. After incubation for 8 h at 37 degreesC in a humidified incubator with 5% CO2 and 95% air, the nonmigrating cells on the top of Boyden chamber were scraped and washed. The migrating cells were quantitated according to manufacturer's instructions. Briefly, the cells were stained and the color eluted with 300 mul of extraction buffer, and 150-mul aliquots were measured in an ELISA plate reader at 545 nm. All assays were performed in duplicate. In parallel experiments, A549 cells and fibroblasts were pretreated as described above for growth rate.
###end p 37
###begin title 38
RNA Isolation and Northern Blot Analysis
###end title 38
###begin p 39
###xml 425 427 423 425 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b21">21</xref>
###xml 1002 1004 981 983 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1407 1409 1376 1378 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1164 1169 <span type="species:ncbi:9606">human</span>
###xml 1256 1261 <span type="species:ncbi:9606">Human</span>
Total RNA was extracted from lung fibroblasts and A549 epithelial cells using the RNeasy Mini Kit (Qiagen GmbH, Germany). Cells were lysed and homogenized in the presence of a highly denaturing guanidine isothiocyanate-containing buffer. The samples were then applied to an RNeasy minicolumn, and RNA was eluted in 30 mul of water. Total RNA (20 mug/lane) was fractionated on a 1% agarose gel containing 0.66 M formaldehyde [21]. Ribosomal RNA was visualized with ethidium bromide, and the fractionated RNA was transferred onto a Nytran transfer membrane (NEN Life Science Products, Boston, Massachusetts, United States) by capillary blotting overnight. RNA was immobilized by baking at 80 degreesC for 2 h, and then prehybridized at 42 degreesC for 18 h in 5x SSC, 50% formamide, 5x Denhardt's solution, and 0.5% SDS, containing 100 mug/ml of denatured salmon sperm DNA. Hybridization was carried out at 42 degreesC for 18 h in hybridization buffer composed of formamide, 0.5% SDS, and heat-denatured 32P-labeled cDNA probes. After washing, membranes were dried and exposed to Kodak BIOMAX MS film at -70 degreesC with an intensifying screen. The cDNA clones for human MMP-1, TIMP-1, alpha1 type I collagen, and RNA ribosomal 18S were obtained from ATCC. Human MMP-7 cDNA was a kind gift of Lynn Matrisian, Vanderbilt University, Nashville, Tennessee, United States. The cDNA probes were radiolabeled with 32P-dCTP to a specific activity of 200 x 106 dpm/mug using a Random Primer Labeling Kit (Stratagene, La Jolla, California, United States). All experiments were repeated twice. 
###end p 39
###begin title 40
Quantitative Real-Time RT-PCR
###end title 40
###begin p 41
###xml 198 219 <span type="species:ncbi:11786">murine leukemia virus</span>
1 mug of RNA was treated with 1 unit of DNAase (Life Technologies, Grand Island, New York, United States). First-strand cDNA was synthesized by reverse transcription with random primers and Moloney-murine leukemia virus reverse transcriptase according to manufacturer's protocol (Advantage RT-for-PCR Kit; Clontech, Palo Alto, California, United States).
###end p 41
###begin p 42
###xml 379 380 377 378 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 723 724 717 718 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 734 735 728 729 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1471 1478 1441 1448 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pmed-0020251-t002">Table 2</xref>
Real-time PCR amplification was performed using i-Cycler iQ Detection System (BioRad, Hercules, California, United States), using TAQMAN probes (PE Applied Biosystems, Wellesley, California, United States) labeled with FAM and TET. PCR was performed with the cDNA working mixture in a 25-mul reaction volume containing 3 mul of cDNA, 20 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 200 muM dNTPs, 0.2 muM specific 5' and 3' primers for 18S rRNA, 0.6 muM specific 5' and 3' primers for gene target, 0.2 muM of each probe TAQMAN (18S rRNA and gene target), and 1.25 units of AmpliTaq GOLD DNA polymerase (PE Applied Biosystems). A dynamical range was built with each product of PCR on copy number serial dilutions from 1 x 108 to 1 x 101; all PCRs were performed in triplicate. Standard curves were calculated referring the threshold cycle (Ct) to the log of each cDNA dilution step. Results were expressed as the number of copies of the target gene normalized to 18S rRNA. Some primers used in PCR reactions were designed using Beacon Designer software 2.1 (BioRad) and checked for homology in BLAST. The cycling conditions for PCR amplification were performed using the following protocol: Initial activation of AmpliTaq Gold DNA polymerase at 95 degreesC for 7 min; and 40 cycles of denaturation at 95 degreesC for 30s, annealing at 60 degreesC for 30 s, and extension at 72 degreesC for 30 s. The sequences of the PCR primer pairs and probes for each gene are shown in Table 2. All PCR experiments were done in duplicate.
###end p 42
###begin title 43
PAGE Zymography
###end title 43
###begin p 44
###xml 147 149 147 149 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b22">22</xref>
###xml 310 311 304 305 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 326 327 320 321 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 100 106 <span type="species:ncbi:9913">bovine</span>
###xml 524 529 <span type="species:ncbi:9606">human</span>
For MMP-7 analysis, conditioned media was electrophoresed in 12.5% SDS gels containing as substrate bovine CM-transferrin (0.3 mg/ml) and heparin [22]. After electrophoresis, gels were washed in a solution of 2.5% Triton X-100, and incubated overnight at 37 degreesC in 100 mM glycine (pH 7.6), plus 10 mM CaCl2 and 50 nM ZnCl2. Identical gels were incubated but in the presence of 20 mM EDTA. Gels were stained with Coomassie Brilliant Blue R250 and destained in a solution of 7.5% acetic acid and 5% methanol. Recombinant human MMP-7 (Chemicon) was used as positive control.
###end p 44
###begin title 45
Western Blot Analysis
###end title 45
###begin p 46
###xml 52 53 52 53 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 539 545 <span type="species:ncbi:9986">rabbit</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 686 691 <span type="species:ncbi:9606">human</span>
###xml 723 728 <span type="species:ncbi:9606">human</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
Serum-free conditioned media was centrifuged at 300 g at 4 degreesC for 30 min to remove cell debris, then concentrated by lyophilization. Samples were solubilized in water, and aliquots containing 5 mug of protein were mixed with Laemmli sample buffer and electrophoresed on 10% or 12.5% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose filters at 15 V for 20 min using semi-dry transfer cell (BioRad). Nonspecific sites were blocked overnight with 4% (w/v) nonfat dried milk in PBS, and membranes were incubated with rabbit antibody to human interstitial collagenase IgG (1:250 in PBS with 1% BSA; Santa Cruz Biotechnology, California, United States), antibody to human TIMP-1 (Chemicon), antibody to human MMP-7 (Oncogene, San Diego, California, United States), or monoclonal antibody to human alpha-smooth muscle actin (2 mug/ml; Cymbus Biotechnology, Chandlers Ford, Hants, United Kingdom) for 2 h at room temperature. Filters were incubated with secondary antibody conjugated to peroxidase for 1 h at room temperature. Finally, the filters were developed with the Enhanced Chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, New Jersey, United States) using radiograph film (Hyperfilm, Amersham Pharmacia Biotech) according to the instructions of the manufacturer. Western blots were repeated twice.
###end p 46
###begin title 47
Results
###end title 47
###begin title 48
###xml 0 11 0 11 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Osteopontin</italic>
Osteopontin Gene Expression Is Highly Up-Regulated in IPF Lungs
###end title 48
###begin p 49
###xml 206 217 206 217 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Osteopontin</italic>
###xml 295 303 295 303 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g001">Figure 1</xref>
###xml 418 426 418 426 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g001">Figure 1</xref>
###xml 546 547 546 547 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 582 583 582 583 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 689 691 689 691 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b23">23</xref>
###xml 780 788 780 788 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g001">Figure 1</xref>
The complete microarray dataset is available at the Gene Expression Omnibus database with GEO serial accession number GSE2052 (). Gene expression patterns clearly distinguished IPF lungs from normal lungs. Osteopontin was the most up-regulated gene among the genes that distinguished IPF lungs (Figure 1A). Osteopontin levels were increased more than 20-fold (mean expression 0.62 in control lungs, 16.8 in IPF lungs; Figure 1B). This increase was statistically significant whether we applied threshold number of misclassifications (TNoM) score (p = 0.000221), or Student's t-test (p = 0.0000035). We corrected for multiple testing by controlling the false discovery rate at the 5% level [23]. Osteopontin expression levels were higher in most IPF lungs than in any control lung (Figure 1B).
###end p 49
###begin title 50
###xml 47 55 <span type="species:ncbi:9606">Patients</span>
Osteopontin Is Increased in BAL Fluid from IPF Patients
###end title 50
###begin p 51
###xml 107 115 107 115 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g002">Figure 2</xref>
###xml 313 314 309 310 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Osteopontin protein was quantified in BAL fluids from 18 IPF patients and 10 healthy controls. As shown in Figure 2, ELISA measurement revealed a significant increase in the immunoreactive protein in the fluids derived from IPF lungs (148.8 +/- 83 ng/ml in IPF lungs versus 3.8 +/- 2.0 ng/ml in healthy controls, p < 0.01).
###end p 51
###begin title 52
Immunoreactive Osteopontin Is Localized Primarily in Epithelial Cells
###end title 52
###begin p 53
###xml 123 131 123 131 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g003">Figure 3</xref>
###xml 133 134 133 134 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g003">3</xref>
###xml 330 338 330 338 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g003">Figure 3</xref>
###xml 481 489 481 489 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g003">Figure 3</xref>
To examine the cellular source of osteopontin we analyzed IPF and control lungs by immunohistochemistry. As illustrated in Figure 3A-3C, osteopontin was localized primarily in alveolar epithelial cells that exhibited an intense cytoplasmic staining in IPF lungs. Occasionally, clusters of alveolar macrophages were also positive (Figure 3C). Immunohistochemical staining for osteopontin was negative in normal lungs as well as in lung tissue samples incubated with nonimmune sera (Figure 3D).
###end p 53
###begin title 54
Osteopontin Induces Fibroblast and Epithelial Cell Growth Rate
###end title 54
###begin p 55
###xml 424 425 422 423 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 547 548 545 546 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
To determine the effect of osteopontin on the growth rates of fibroblasts and epithelial cells, cells were stimulated with increasing concentrations of osteopontin, and the cell number was determined after 48 h using the cell proliferation reagent WST-1. Significant dose-dependent increases in cell proliferation were observed with 1 mug/ml and 2 mug/ml. Two different fibroblast lines reached 220% and 380% over controls (p < 0.01), while in two different experiments A549 cell lines exhibited 60% and 80% increases of growth rate over control (p < 0.01).
###end p 55
###begin p 56
###xml 187 188 186 187 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 221 222 216 217 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 226 227 218 219 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 238 239 230 231 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 383 384 371 372 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 388 389 373 374 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 400 408 385 393 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g004">Figure 4</xref>
###xml 493 494 478 479 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 504 512 489 497 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g004">Figure 4</xref>
###xml 612 613 593 594 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 617 618 595 596 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 620 628 598 606 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g004">Figure 4</xref>
Osteopontin-induced fibroblast proliferation (2 mug/ml) was significantly suppressed by GRGDS-pentapeptide, which interrupts binding of RGD-containing proteins to cell surface integrins (p < 0.01) and by antibody to alphavbeta3 integrin (p < 0.05), suggesting that the effect of osteopontin on growth rate was mediated by the interaction of the GRGDS domain of osteopontin with alphavbeta3 integrin (Figure 4A). In contrast, epithelial cell growth was partially inhibited by antibody to CD44 (p < 0.05) (Figure 4B). Epithelial cell growth was also significantly suppressed by GRGDS but not by antibodies to alphavbeta3 (Figure 4B).
###end p 56
###begin title 57
Osteopontin Induces Fibroblast and Epithelial Cell Migration
###end title 57
###begin p 58
###xml 250 258 250 258 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g005">Figure 5</xref>
###xml 458 459 455 456 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 818 819 809 810 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 823 824 811 812 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 835 836 823 824 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 871 872 859 860 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
To examine the effect of osteopontin on cell migration, we used collagen-coated Boyden chambers, a well-established in vitro assay system. The number of cells that migrated in absence of osteopontin was used as control (0% migration). As revealed in Figure 5A, fibroblasts significantly moved toward osteopontin compared with cells exposed to medium plus 5% BSA alone in the lower chamber. Osteopontin (10 mug) enhanced fibroblast migration by 120% +/- 11% (p < 0.01), an enhancement similar to that obtained with the potent fibroblast mitogen platelet-derived growth factor, used as a positive control (157% +/- 12%, unpublished data). To analyze possible mechanisms by which osteopontin stimulates migration, different blockers were used. Fibroblast migration was significantly reduced by GRGDS and antibody to alphavbeta3 integrin (p < 0.01), and by antibody to CD44 (p < 0.05). The inhibition of cell migration was specific, since incubation with IgG had no effect (unpublished data).
###end p 58
###begin p 59
###xml 97 105 97 105 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g005">Figure 5</xref>
###xml 227 228 225 226 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 482 483 474 475 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 487 488 476 477 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 513 514 502 503 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 523 531 512 520 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g005">Figure 5</xref>
A549 lung cells also showed a significant increase in cell migration in response to osteopontin (Figure 5B). After 8 h of incubation, A549 cells passing through the membrane increased by 114% +/- 25% compared to control cells (p < 0.01). Epidermal growth factor, used as a positive control, induced a 168% +/- 14% increase in cell migration (unpublished data). Osteopontin-induced migration was abolished when the epithelial cells were pretreated individually with GRGDS, anti-alphavbeta3 integrin, or anti-CD44 (p < 0.01; Figure 5B).
###end p 59
###begin title 60
Osteopontin Induces an Environment That Favors Extracellular Matrix Deposition in Fibroblasts
###end title 60
###begin title 61
MMP-1 expression by fibroblasts
###end title 61
###begin p 62
###xml 426 434 426 434 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g006">Figure 6</xref>
###xml 440 441 440 441 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g006">6</xref>
###xml 762 763 738 739 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 772 780 748 756 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g006">Figure 6</xref>
###xml 904 905 876 877 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 909 910 878 879 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1044 1052 1013 1021 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g006">Figure 6</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
Under basal conditions, some primary human lung fibroblast cell lines may express MMP-1, while others express the enzyme only when stimulated, for example, by aminophenylmercuric acetate (APMA). In this context, the effect of osteopontin on MMP-1 expression was examined by Northern blot analysis in a cell line producing MMP-1 under basal conditions, and in a cell line that did not produce MMP-1 but was stimulated by APMA (Figure 6A and 6B). Osteopontin down-regulated both the basal and the APMA-induced MMP-1 transcript level. When the signal of MMP-1 mRNA was normalized to the level of 18S RNA and quantified by densitometry, a reduction of approximately50% was noticed. This result was confirmed by real-time PCR that showed approximately40% inhibition (p < 0.05; Figure 6C). Inhibition of MMP-1 expression was partially blocked by antibody to CD44, while it was not affected by antibody to alphavbeta3 integrin. The inhibitory effect of osteopontin on MMP-1 was also observed at the protein level by Western blot analysis. As shown in Figure 6D, the level of immunoreactive MMP-1 present in the conditioned medium was decreased in the fibroblasts stimulated with osteopontin as compared with control cells.
###end p 62
###begin title 63
###xml 54 54 54 54 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
Osteopontin increases TIMP-1 expression by fibroblasts
###end title 63
###begin p 64
###xml 29 35 29 35 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TIMP-1</italic>
###xml 85 93 85 93 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g007">Figure 7</xref>
###xml 119 127 119 127 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g007">Figure 7</xref>
###xml 154 160 154 160 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TIMP-1</italic>
###xml 286 294 284 292 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g007">Figure 7</xref>
###xml 401 402 395 396 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 441 442 431 432 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 446 447 433 434 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 575 583 562 570 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g007">Figure 7</xref>
The effect of osteopontin on TIMP-1 gene expression in fibroblasts is illustrated in Figure 7. Northern blot analysis (Figure 7A) revealed an increase in TIMP-1 gene expression at 0.4 mug/ml and 1 mug/ml osteopontin when compared to control. This result was confirmed by real-time PCR (Figure 7B). Osteopontin increased the TIMP-1/18S ribosomal RNA from 55.7 +/- 14.2 copies to 121.2 +/- 13.1 copies (p < 0.01). Both anti-CD44 and anti-alphavbeta3 integrin abolished this increase. Osteopontin also increased TIMP-1 protein expression in conditioned medium as illustrated in Figure 7C.
###end p 64
###begin title 65
Osteopontin induces collagen gene expression in fibroblasts
###end title 65
###begin p 66
###xml 69 77 69 77 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g008">Figure 8</xref>
###xml 103 111 103 111 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g008">Figure 8</xref>
###xml 144 166 144 162 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#945;1 type I collagen</italic>
###xml 288 296 277 285 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g008">Figure 8</xref>
The effect of osteopontin on collagen gene expression is depicted in Figure 8. Northern blot analysis (Figure 8A) revealed a 2-fold increase in alpha1 type I collagen gene expression. Expression of alpha-smooth muscle actin in fibroblasts was induced by TGF-beta1 but not by osteopontin (Figure 8B).
###end p 66
###begin title 67
Osteopontin Increases MMP-7 Expression by Epithelial Cells
###end title 67
###begin p 68
###xml 156 164 154 162 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g009">Figure 9</xref>
###xml 294 295 288 289 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 299 300 290 291 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 345 353 336 344 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g009">Figure 9</xref>
###xml 485 493 476 484 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g009">Figure 9</xref>
###xml 944 952 933 941 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g009">Figure 9</xref>
Stimulation of A549 cells with osteopontin (0.4 mug/ml and 2.0 mug/ml) induced an up-regulation of MMP-7 gene expression as illustrated by Northern blot in Figure 9A. Real-time PCR revealed a 6-fold increase at 6 h after osteopontin stimulation, which was abolished by treatment with anti-alphavbeta3, anti-CD44, anti-EGFR, or GRGDS as shown in Figure 9B. Pro-MMP-7 overexpression was confirmed at the protein level by Western blot analysis of the epithelial cells conditioned medium (Figure 9C). As recombinant MMP-7 used as control showed a lower molecular weight band to that of conditioned medium, this one was treated with APMA to activate pro-MMP-7. Activated proenzyme showed a similar molecular weight band to the recombinant protein. Zymography using CM-transferrin as substrate showed that treatment of A549 epithelial cells with 0.4 mug/ml and 1 mug/ml osteopontin induced an increase of both the pro-MMP-7 and MMP-7 activity bands (Figure 9D).
###end p 68
###begin title 69
Osteopontin Colocalizes with MMP-7 in Alveolar Epithelial Cells from IPF Lungs
###end title 69
###begin p 70
###xml 106 108 106 108 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b14">14</xref>
###xml 208 217 208 217 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g010">Figure 10</xref>
###xml 277 286 277 286 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g010">Figure 10</xref>
###xml 339 348 339 348 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g010">Figure 10</xref>
###xml 388 397 388 397 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g010">Figure 10</xref>
###xml 403 405 403 405 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g010">10</xref>
Since we have previously demonstrated that IPF lungs strongly express MMP-7 in alveolar epithelial cells [14], we evaluated whether the staining pattern of this enzyme is associated with that of osteopontin. Figure 10 illustrates confocal microscopy images showing that MMP-7 (Figure 10A) is partially overlapped with that of osteopontin (Figure 10B), giving substantial double labeling (Figure 10C and 10D). Normal lungs did not exhibit any significant staining for MMP-7 or osteopontin (unpublished data).
###end p 70
###begin title 71
Weakest Link Models Identify a Statistically Significant Interaction between Osteopontin and MMP-7
###end title 71
###begin p 72
###xml 150 152 150 152 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b20">20</xref>
###xml 587 588 587 588 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 641 650 641 650 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g011">Figure 11</xref>
###xml 688 697 688 697 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g011">Figure 11</xref>
###xml 728 737 728 737 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g011">Figure 11</xref>
###xml 950 959 950 959 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pmed-0020251-g011">Figure 11</xref>
###xml 1205 1206 1205 1206 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1339 1350 1339 1350 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 1509 1520 1509 1520 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 1035 1040 <span type="species:ncbi:9606">Human</span>
To determine whether MMP-7 and osteopontin expression levels jointly distinguish IPF and control samples, we applied weakest link statistical models [20]. Weakest link models assume that two genes jointly impact the probability that a randomly selected sample belongs to a certain phenotype (IPF in this case) only if expression levels of the two genes lie on a low-dimensional curve whose form is specified by the model and estimated using the observed quantiles of the data. Our analysis detected a statistically significant joint effect of MMP-7 and osteopontin on the IPF phenotype (p < 0.001). This joint relationship is illustrated in Figure 11 for both the gene expression values (Figure 11A) and the sample percentiles (Figure 11B). To assess the relevance of this association, we chose both substantively meaningful genes and a more general set of genes to evaluate the contribution of the weakest link model relating osteopontin and MMP-7 (Figure 11). Among 14 matrix metalloproteases and their inhibitors represented on the Human Uniset I chip, osteopontin and MMP-7 exhibited the most significant biological interaction. Osteopontin also had significant interactions (weakest link models with p < 0.05) with MMP-1, MMP-2, and MMP-11 but none was as statistically significant as MMP-7. We also ran weakest link models combining osteopontin with each of 400 genes that passed the false discovery rate of less than 0.05 for differential expression between IPF and control samples. The interaction of osteopontin with MMP-7 in a weakest link model was more significant than 371 of these 400 genes.
###end p 72
###begin title 73
Discussion
###end title 73
###begin p 74
###xml 238 239 238 239 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b08">8</xref>
###xml 240 242 240 242 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b11">11</xref>
###xml 243 245 243 245 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b12">12</xref>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
In the present study we focused on the profibrotic effects of osteopontin, a multifunctional cytokine that mediates diverse biological functions, including cell adhesion, chemotaxis, and signaling, as well as tissue reparative processes [8,11,12]. We demonstrated that osteopontin was the most up-regulated gene in lungs of IPF patients, and that it was mainly expressed by alveolar epithelial cells. To better understand the potential local profibrotic effects of osteopontin, we studied its effects on lung fibroblasts and epithelial cells. Functionally, osteopontin induced fibroblast and epithelial cell proliferation and migration. The effect on fibroblast migration and proliferation was dependent mainly on integrins, while in epithelial cells proliferation was mainly dependent on CD44 and migration was dependent on CD44 and integrin signaling. Osteopontin exhibited profibrotic effects on molecules involved in extracellular matrix remodeling. Thus, in fibroblasts, osteopontin increased TIMP-1 and type I collagen and inhibited MMP-1 expression, while in alveolar epithelial cells it induced MMP-7. The effects on TIMP-1 and MMP-1 expression appeared to be mostly dependent on CD44, while the effect on MMP-7 expression was dependent on CD44 and integrin signaling. Interestingly, osteopontin was colocalized with MMP-7 in alveolar epithelial cells of IPF lungs, and application of the weakest link models to microarray data suggested that the genes of both interacted to affect the IPF phenotype. Our results provide a potential mechanism by which osteopontin secreted from epithelial cells exerts its profibrotic effects through direct signaling on fibroblasts and epithelial cells.
###end p 74
###begin p 75
###xml 252 254 252 254 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b24">24</xref>
###xml 428 430 428 430 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b25">25</xref>
###xml 624 626 624 626 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b26">26</xref>
###xml 767 769 767 769 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b15">15</xref>
###xml 770 772 770 772 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b16">16</xref>
###xml 896 898 896 898 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b27">27</xref>
###xml 899 901 899 901 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b28">28</xref>
###xml 1074 1076 1074 1076 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b15">15</xref>
###xml 1077 1079 1077 1079 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b16">16</xref>
###xml 924 929 <span type="species:ncbi:9606">human</span>
Several studies in experimental tissue fibrosis have suggested a possible profibrotic role of osteopontin. In kidney fibrosis, osteopontin enhances macrophage recruitment and stimulates the development of renal scarring after an acute ischemic insult [24]. Also, osteopontin expression is increased in the myocardium after myocardial infarction, and the lack of this mediator is associated with decreased collagen accumulation [25]. Similarly, osteopontin appears to be an important mediator of the cardiac profibrotic effects of angiotensin II by promoting collagen synthesis and remodeling in the interstitial myocardium [26]. In experimental lung fibrosis it has been suggested that osteopontin produced by alveolar macrophages functions as a fibrogenic cytokine [15,16]. In granulomatous lung diseases, osteopontin is also up-regulated and its main sources are macrophages and T lymphocytes [27,28]. We observed that in human IPF lungs, hyperplastic alveolar epithelial cells seemed to be a source of osteopontin, which is consistent with the findings of Berman et al. [15,16]. These observations support the key role of alveolar epithelial cells as regulators of the lung profibrotic microenvironment in IPF, thus emphasizing the critical difference between the mechanisms of fibrosis in IPF compared with animal models or with lung fibrosis associated with inflammatory disorders.
###end p 75
###begin p 76
###xml 86 88 86 88 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b29">29</xref>
###xml 135 137 135 137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b30">30</xref>
###xml 178 180 178 180 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b29">29</xref>
###xml 334 336 334 336 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b31">31</xref>
###xml 397 399 397 399 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b31">31</xref>
###xml 768 773 768 773 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MMP-7</italic>
###xml 778 789 778 789 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 821 823 818 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b32">32</xref>
###xml 824 826 821 823 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b33">33</xref>
###xml 919 921 913 915 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b34">34</xref>
###xml 1055 1057 1046 1048 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b34">34</xref>
Positive feedback mechanisms have been previously proposed for osteopontin and MMP-2 [29], where osteopontin induces MMP-2 expression [30] and is cleaved and activated by MMP-2 [29]. The same mechanism has been proposed for osteopontin and MMP-3, where osteopontin binds and activates MMP-3, which in turn can cleave and activate it [31]. Similarly, osteopontin is cleaved and activated by MMP-7 [31], and we observe that MMP-7 is induced by osteopontin in epithelial cells, suggesting that this positive feedback mechanism is also applicable to osteopontin and MMP-7. This is also supported by the colocalization of MMP-7 and osteopontin in IPF epithelial cells, and by the computational relationship of the expression levels of osteopontin and MMP-7. Interestingly, MMP-7 and osteopontin are beta-catenin target genes [32,33]. Recently, Chilosi et al. reported impressive activation of WNT/beta-catenin in IPF lungs [34]. They have mainly observed beta-catenin nuclear localization in proliferative bronchiolar lesions, where it colocalized with MMP-7 [34]. Collectively, these results could indicate a mechanism by which osteopontin and MMP-7 are induced by aberrant activation of the WNT/beta-catenin pathway, and each affects the function and expression of the other gene, thus representing a local positive feedback mechanism that facilitates a chronic, relentless lung disease.
###end p 76
###begin p 77
###xml 429 431 426 428 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b35">35</xref>
###xml 744 759 741 756 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">type I collagen</italic>
###xml 1011 1013 1008 1010 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b36">36</xref>
###xml 1014 1016 1011 1013 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b37">37</xref>
###xml 454 459 <span type="species:ncbi:9606">human</span>
Although intriguing, this proposed positive, self-perpetuating loop in itself cannot explain increased collagen deposition, the critical hallmark of fibrosis. In this context, our results suggest that osteopontin affects the critical balance between MMPs and their inhibitors through its cell-specific effects. In agreement with the inhibition of interleukin 1beta-stimulated increases in MMP-2 and MMP-9 observed by Xie et al. [35], we observed that in human lung fibroblasts, osteopontin caused a significant reduction of baseline as well as APMA-stimulated MMP-1, an MMP responsible for fibrillar collagen degradation. Additionally, we observed a concomitant increase in TIMP-1, the main inhibitor of MMP-1 (as well as MMP-2 and -9), and in type I collagen gene expression, suggesting that osteopontin may facilitate a profibrotic environment not only by its effect on epithelial cells but also by inducing a nondegradative microenvironment similar to the one observed in IPF and experimental lung fibrosis [36,37]. Interestingly, osteopontin did not induce alpha-smooth muscle actin in lung fibroblasts in vitro, suggesting that although it had a role in facilitating the profibrotic environment in IPF, it had weaker role in the formation of myofibroblast foci. However, further experiments will be needed to determine this point.
###end p 77
###begin p 78
###xml 218 219 218 219 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b05">5</xref>
###xml 473 475 473 475 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b15">15</xref>
###xml 723 725 723 725 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b38">38</xref>
###xml 886 888 886 888 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b39">39</xref>
###xml 889 891 889 891 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b40">40</xref>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 433 439 <span type="species:ncbi:10090">murine</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 539 542 <span type="species:ncbi:10116">rat</span>
Migration and proliferation of fibroblasts are essential for the expansion of their populations and the formation of the fibroblastic foci that seem to represent the "leading edge" of the progressive fibrotic process [5]. The observation that osteopontin induced both migration and proliferation of primary human lung fibroblasts suggests that osteopontin may be involved in this process and is supported by previous observations in murine and human fibroblast cell lines [15]. Osteopontin promotes fibroblast collagen gel contraction and rat cardiac fibroblast proliferation, and it has been suggested that it is an important mediator of angiotensin II regulation of fibroblast behavior in the cardiac remodeling process [38]. It also induced proliferation of vessel smooth muscle cells, suggesting that it is involved in vascular remodeling during the development of atherosclerosis [39,40]. These results highlight the sufficiency of a cytokine secreted from alveolar epithelial cell to induce many of the phenotypic changes associated with lung fibrosis.
###end p 78
###begin p 79
###xml 226 228 226 228 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b41">41</xref>
###xml 229 231 229 231 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b42">42</xref>
###xml 369 371 369 371 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b43">43</xref>
###xml 441 443 441 443 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b44">44</xref>
###xml 477 479 477 479 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b45">45</xref>
###xml 549 551 549 551 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b46">46</xref>
###xml 656 658 656 658 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b47">47</xref>
###xml 1271 1272 1267 1268 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1276 1277 1269 1270 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1623 1625 1616 1618 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b48">48</xref>
###xml 1766 1768 1759 1761 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b10">10</xref>
###xml 1769 1771 1762 1764 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b49">49</xref>
###xml 1772 1774 1765 1767 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pmed-0020251-b50">50</xref>
The mechanisms by which osteopontin influences epithelial and fibroblast cells are not fully understood. In general it has been proposed that osteopontin affects cells by binding to CD44 isoforms, certain integrins, and EGFR [41,42]. It is unknown whether the expression of these receptors is changed in IPF; CD44 is expressed on lung fibroblasts and epithelial cells [43], is induced in radiation- and bleomycin-induced pulmonary fibrosis [44] and in acute alveolar fibrosis [45], and is critical for resolution of noninfectious lung inflammation [46]. The integrin receptors for osteopontin are widely expressed in lung epithelial cells and fibroblasts [47], but a change in their repertoire has not been reported yet with IPF. In this paper we did not seek to fully dissect these mechanisms; however, we explored some of the possible receptors that may be important to osteopontin effect on fibroblasts and epithelial cells. Our results support some of the previous observations regarding the importance of integrin-mediated signaling in fibroblast migration. Interestingly, we observed a differential effect in epithelial and fibroblasts cells. Inhibition of CD44 significantly reduced the effects of osteopontin on cell proliferation in epithelial cells, while alphavbeta3 inhibition seemed to affect mostly fibroblasts. This integrin is a receptor for a wide variety of extracellular matrix ligands with an exposed RGD sequence, including vitronectin, fibronectin, fibrinogen, thrombospondin, proteolyzed collagen, von Willebrand factor, as well as osteopontin, and appears to play a critical role in cell migration [48]. The hyaluronic acid receptor CD44 is also a receptor for osteopontin, and it has been implicated in chemotaxis mediated by this mediator [10,49,50]. In our experiments, the pan-integrin antagonist GRGDS-pentapeptide added to the culture medium abolished the effects in fibroblasts and epithelial cells, suggesting that different integrins may be involved in both cell types, and that for some effects, both integrins and CD44 are required. Detailed studies of the effects of variant osteopontin isoforms as well as cells that express different receptors will be needed to elucidate these mechanisms.
###end p 79
###begin p 80
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 318 323 <span type="species:ncbi:9606">human</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 602 607 <span type="species:ncbi:9606">human</span>
Our study focused on human tissues and human cell lines because of the unique features of IPF that are not readily mimicked by any animal models. We insisted on using primary human lung fibroblasts in our experiments; therefore, we are confident that these results represent a mechanism that may actually occur in the human lung. Unfortunately, it is nearly impossible to work with primary alveolar epithelial cells, and we had to resort to the epithelial cell line A549. However, we present evidence obtained from human lungs that suggest that the mechanisms that we proposed in vitro do exist in the human IPF lung.
###end p 80
###begin p 81
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 217 222 <span type="species:ncbi:9606">human</span>
In summary, in this study we highlight the role of osteopontin in human IPF. Although previous studies have suggested that osteopontin has a potential profibrotic effect in animal models of lung fibrosis, its role in human IPF was unclear. We demonstrated that osteopontin is highly expressed in IPF lungs, and that it is primarily expressed by hyperplastic alveolar epithelial cells. We demonstrated that osteopontin affected fibroblast and epithelial cell proliferation and migration, and that it had fibrosis-relevant effects on MMP and TIMP expressions. Our results suggest a mechanism explaining most of the profibrotic effects of osteopontin by its direct effects on fibroblasts and epithelial cells in the lungs. Furthermore, our results suggest that in IPF the interaction between MMP-7 and osteopontin may be involved in the relentlessly progressive nature of the disease, and highlight osteopontin as a potential target for therapeutic intervention in this incurable disease.
###end p 81
###begin title 82
Supporting Information
###end title 82
###begin title 83
Sample Mexico
###end title 83
###begin p 84
(746 KB ZIP).
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin title 86
Microarrays
###end title 86
###begin p 87
(2.1 MB ZIP).
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
Accession Numbers
###end title 89
###begin p 90
###xml 74 78 74 78 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R18S</italic>
###xml 89 94 89 94 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MMP-1</italic>
###xml 108 113 108 113 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MMP-7</italic>
###xml 131 137 131 137 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">TIMP-1</italic>
The GenBank () accession numbers of the genes discussed in this paper are R18S (X03205), MMP-1 (NM_002421), MMP-7 (XM_017384), and TIMP-1 (X03124).
###end p 90
###begin title 91
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient summary
###end title 91
###begin title 92

###end title 92
###begin title 93
Background
###end title 93
###begin p 94
###xml 202 210 <span type="species:ncbi:9606">Patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
Idiopathic pulmonary fibrosis is a chronic progressive disease of the lung that leads to increasing amounts of scar tissue with subsequent destruction of the lung. There is no specific cure at present. Patients may be treated with corticosteroids or drugs to suppress their immune system, although these drugs are usually not effective. Some patients receive lung transplants.
###end p 94
###begin title 95
Why Was This Study Done?
###end title 95
###begin p 96
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 275 280 <span type="species:ncbi:9606">human</span>
Previous work has suggested that a protein called osteopontin is increased in mice that have lung fibrosis and that mice that do not have the gene for osteopontin are protected from lung fibrosis. The researchers wanted to investigate if osteopontin was also involved in the human disease.
###end p 96
###begin title 97
What Did the Researchers Do and Find?
###end title 97
###begin p 98
###xml 47 53 <span type="species:ncbi:9606">people</span>
###xml 216 222 <span type="species:ncbi:9606">people</span>
They looked at samples taken from the lungs of people with idiopathic pulmonary fibrosis and other diseases and measured many genes that are expressed there. They found that osteopontin was increased in the lungs of people with idiopathic pulmonary fibrosis. They then looked at cultures of lung cells and found that osteopontin caused an increase in the number and movement of cells that are involved in lung fibrosis. Its presence also affected other proteins that seem to be involved in fibrosis.
###end p 98
###begin title 99
What Do These Findings Mean?
###end title 99
###begin p 100
###xml 93 99 <span type="species:ncbi:9606">people</span>
Osteopontin may have a key role in the pathway that causes fibrosis to occur in the lungs of people with idiopathic pulmonary fibrosis. Further work will need to be done to confirm these results, but in the future drugs directed against osteopontin or one of the related proteins might be a possible treatment for the disease. Currently there are no such drugs. Additionally osteopontin may be useful in the diagnosis and early detection of the disease, but further studies are required.
###end p 100
###begin title 101
Where Can I Get More Information Online?
###end title 101
###begin p 102
Medline Plus has links to many pages with information on the disease:
###end p 102
###begin p 103

###end p 103
###begin p 104
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The Coalition for Pulmonary Fibrosis is a nonprofit organization that has information for patients as well as physicians:
###end p 104
###begin p 105

###end p 105
###begin p 106
###xml 111 119 <span type="species:ncbi:9606">patients</span>
The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases contains information about IPF for patients and their families:
###end p 106
###begin p 107

###end p 107
###begin p 108
The authors wish to acknowledge Inna Loutaev and Lara Chensny for their technical help and Mary Williams for her help in administering the collaborative efforts that underlie this manuscript. The authors also thank Dr. A. Choi, Dr. J. Dauber, and Dr. N. Friedman for their critical review and insightful comments. This work was supported National Institutes of Health grant 1R01 HL073745-01 and by a generous donation from the Simmons family. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 108
###begin title 109
References
###end title 109
###begin article-title 110
Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
###end article-title 110
###begin article-title 111
Idiopathic pulmonary fibrosis
###end article-title 111
###begin article-title 112
Treatment of idiopathic pulmonary fibrosis: The rise and fall of corticosteroids
###end article-title 112
###begin article-title 113
Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification
###end article-title 113
###begin article-title 114
Future research directions in idiopathic pulmonary fibrosis: Summary of a National Heart, Lung, and Blood Institute working group
###end article-title 114
###begin article-title 115
American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)
###end article-title 115
###begin article-title 116
ATS/ERS International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the ATS and the ERS was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001
###end article-title 116
###begin article-title 117
###xml 63 66 <span type="species:ncbi:9615">dog</span>
Osteopontin (Eta-1) in cell-mediated immunity: Teaching an old dog new tricks
###end article-title 117
###begin article-title 118
Osteopontin-A possible anchor of osteoclasts to bone
###end article-title 118
###begin article-title 119
Receptor-ligand interaction between CD44 and osteopontin (Eta-1)
###end article-title 119
###begin article-title 120
Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival
###end article-title 120
###begin article-title 121
Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation
###end article-title 121
###begin article-title 122
Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis
###end article-title 122
###begin article-title 123
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 97 103 <span type="species:ncbi:9606">humans</span>
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans
###end article-title 123
###begin article-title 124
Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis
###end article-title 124
###begin article-title 125
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice
###end article-title 125
###begin article-title 126
High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis
###end article-title 126
###begin article-title 127
Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
###end article-title 127
###begin article-title 128
Practical approaches to analyzing results of microarray experiments
###end article-title 128
###begin article-title 129
###xml 121 129 <span type="species:ncbi:9606">patients</span>
The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma
###end article-title 129
###begin article-title 130
Weakest link models for microarray data in idiopathic pulmonary fibrosis
###end article-title 130
###begin article-title 131
Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression
###end article-title 131
###begin article-title 132
Controlling the false discovery rate: A practical and powerful approach to multiple testing
###end article-title 132
###begin article-title 133
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice
###end article-title 133
###begin article-title 134
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin
###end article-title 134
###begin article-title 135
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy
###end article-title 135
###begin article-title 136
Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro
###end article-title 136
###begin article-title 137
Osteopontin is strongly expressed by histiocytes in granulomas of diverse etiology
###end article-title 137
###begin article-title 138
Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments
###end article-title 138
###begin article-title 139
Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways
###end article-title 139
###begin article-title 140
Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin)
###end article-title 140
###begin article-title 141
###xml 75 80 <span type="species:ncbi:9606">human</span>
Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer
###end article-title 141
###begin article-title 142
Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription
###end article-title 142
###begin article-title 143
Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis
###end article-title 143
###begin article-title 144
###xml 106 109 <span type="species:ncbi:10116">rat</span>
Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: Role of protein kinase C-zeta
###end article-title 144
###begin article-title 145
TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?
###end article-title 145
###begin article-title 146
###xml 156 161 <span type="species:ncbi:10090">mouse</span>
Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains
###end article-title 146
###begin article-title 147
###xml 27 30 <span type="species:ncbi:10116">rat</span>
Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction
###end article-title 147
###begin article-title 148
Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro
###end article-title 148
###begin article-title 149
Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty
###end article-title 149
###begin article-title 150
The role of osteopontin in lung disease
###end article-title 150
###begin article-title 151
Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC
###end article-title 151
###begin article-title 152
CD44: From adhesion molecules to signalling regulators
###end article-title 152
###begin article-title 153
###xml 88 92 <span type="species:ncbi:10116">rats</span>
###xml 102 106 <span type="species:ncbi:9823">pigs</span>
Expression of CD44 isoforms during bleomycin-or radiation-induced pulmonary fibrosis in rats and mini-pigs
###end article-title 153
###begin article-title 154
Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44
###end article-title 154
###begin article-title 155
Resolution of lung inflammation by CD44
###end article-title 155
###begin article-title 156
Functions of pulmonary epithelial integrins: From development to disease
###end article-title 156
###begin article-title 157
The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
###end article-title 157
###begin article-title 158
The hyaluronan receptor, CD44
###end article-title 158
###begin article-title 159
Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: Evidence of a role for an intracellular form of osteopontin
###end article-title 159
###begin title 160
Abbreviations
###end title 160
###begin p 161
aminophenylmercuric acetate
###end p 161
###begin p 162
bronchoalveolar lavage
###end p 162
###begin p 163
epidermal growth factor (receptor)
###end p 163
###begin p 164
idiopathic pulmonary fibrosis
###end p 164
###begin p 165
matrix metalloprotease
###end p 165
###begin p 166
standard deviation
###end p 166
###begin p 167
transforming growth factor-beta 1
###end p 167
###begin p 168
tissue inhibitor of metalloprotease
###end p 168
###begin title 169
Figures and Tables
###end title 169
###begin title 170
Osteopontin Expression Levels by Microarray Analysis from Controls and IPF Lungs
###end title 170
###begin p 171
Total RNA was used to generate double-stranded cDNA and biotin-labeled cRNA. Fragmented cRNA was hybridized to Codelink Uniset I slides and stained and scanned as described in Materials and Methods.
###end p 171
###begin p 172
###xml 194 195 194 195 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
(A) A log scale scatter plot of the average of intensity of all the genes on the arrays in controls (x-axis) and IPF (y-axis). Colored points indicate 178 genes that were significantly changed (p < 0.01 in TNoM and Student's t-test). Points are colored by their fold ratios; progressive shades of blue indicate increase, and progressive shades of red indicate decrease. Points colored in gray did not reach significance. Oblique solid line indicates the line of equality. Two green dashed lines are lines that depict 10-fold change.
###end p 172
###begin p 173
(B) Osteopontin levels in individual samples are shown. The y-axis is expression level in arbitrary fluorescence levels (log scale). The blue quadrangles are osteopontin levels in individual samples. Heat map shows sample osteopontin levels normalized to the geometric mean of osteopontin in controls and log base 2-transformed.
###end p 173
###begin title 174
Osteopontin Levels in BAL Fluid
###end title 174
###begin p 175
###xml 326 327 324 325 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Quantification of osteopontin by ELISA was performed in BAL fluid samples from 18 IPF patients and 10 healthy individual controls. An increased concentration of soluble osteopontin was found in the BAL fluid obtained from IPF patients compared with healthy controls. The data represent the mean +/- standard deviation (SD). * p < 0.01.
###end p 175
###begin title 176
Localization of Osteopontin in IPF Lungs
###end title 176
###begin p 177
Immunoreactive protein was revealed with AEC, and samples were counterstained with hematoxylin. Two representative IPF lung samples exhibited strong epithelial staining (original magnification, 40x) (A,B). Control lung showed no staining (C). Negative control section from IPF lung in which the primary antibody was replaced with nonimmune serum also showed no staining (40x) (D).
###end p 177
###begin title 178
Effect of Osteopontin on Fibroblasts and Epithelial Cell Proliferation
###end title 178
###begin p 179
###xml 222 223 217 218 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 227 228 219 220 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 335 336 325 326 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 347 348 337 338 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human normal lung fibroblasts (A) and A549 epithelial cells (B) were grown in Ham's F-12 medium with 0.1% FBS and stimulated with 2 mug/ml osteopontin. In parallel, osteopontin-stimulated cells were treated with anti-alphavbeta3, anti-CD44, and GRGDS. Each bar represents the mean +/- SD of three experiments performed in triplicate; *p < 0.05; **p < 0.01.
###end p 179
###begin p 180
OPN, osteopontin
###end p 180
###begin title 181
Effect of Osteopontin on Fibroblasts and Epithelial Cell Migration
###end title 181
###begin p 182
###xml 431 432 426 427 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 436 437 428 429 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 520 521 510 511 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 532 533 522 523 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Fibroblasts (A) and A549 epithelial cells (B) were placed in the upper compartment of a Boyden-type chamber, and Ham's F-12 medium containing 5% BSA alone or with 10 mug/ml of osteopontin was added to the lower compartment. After 8 h of incubation, the migrating cells were stained, and the absorbance of the stained solution was measured by ELISA. In parallel experiments, osteopontin-stimulated cells were treated with anti-alphavbeta3, anti-CD44, and GRGDS. Each bar represents the mean +/- SD of three experiments; *p < 0.01; **p < 0.05.
###end p 182
###begin p 183
OPN, osteopontin
###end p 183
###begin title 184
###xml 67 72 <span type="species:ncbi:9606">Human</span>
Effects of Osteopontin on MMP-1 Gene and Protein Expression in Two Human Lung Fibroblast Cell Lines
###end title 184
###begin p 185
(A) Representative Northern blot of 20 mug total cellular RNA per lane extracted from control cells and fibroblasts stimulated with 0.4 mug/ml and 1 mug/ml osteopontin. Both concentrations of osteopontin induced a down-regulation in the expression of MMP-1.
###end p 185
###begin p 186
(B) Osteopontin also reduced overexpression of MMP-1 in APMA-stimulated cells.
###end p 186
###begin p 187
###xml 236 237 232 233 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 241 242 234 235 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 287 288 278 279 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
(C) The expression level of MMP-1 by real-time PCR was determined as described in Materials and Methods and normalized to the level of 18S ribosomal RNA. In parallel experiments, osteopontin-stimulated cells were treated with anti-alphavbeta3 and anti-CD44. Bars represent mean +/- SD (*p < 0.05).
###end p 187
###begin p 188
(D) Representative Western blot demonstrating a decrease of immunoreactive MMP-1 in conditioned media from fibroblasts stimulated with osteopontin. Fibroblasts treated with APMA and FGF-1 plus heparin used as positive controls strongly induced MMP-1 expression.
###end p 188
###begin p 189
C, control; FGF1, FGF-1 plus heparin; OPN, osteopontin; PMA, APMA-stimulated.
###end p 189
###begin title 190
Effect of Osteopontin on TIMP-1 Gene and Protein Expression by Fibroblasts
###end title 190
###begin p 191
(A) Northern blot of 20 mug total cellular RNA per lane extracted from control and fibroblasts stimulated with 0.4 mug/ml and 1 mug/ml osteopontin. Both concentrations of osteopontin induced an increase of TIMP-1 expression.
###end p 191
###begin p 192
###xml 148 149 148 149 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 241 242 237 238 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 246 247 239 240 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
(B) The expression level of TIMP-1 by real-time PCR normalized to the level of 18S ribosomal RNA corroborates TIMP-1 up-regulation by osteopontin (*p < 0.01). In parallel experiments, osteopontin-stimulated cells were treated with anti-alphavbeta3 and anti-CD44.
###end p 192
###begin p 193
(C) Western blot demonstrating an increase of immunoreactive TIMP-1 in conditioned media from fibroblasts stimulated with osteopontin.
###end p 193
###begin p 194
C, control; OPN, osteopontin.
###end p 194
###begin title 195
###xml 92 97 <span type="species:ncbi:9606">Human</span>
Effects of Osteopontin on Collagen Gene Expression and Smooth Muscle Alpha Actin Protein in Human Lung Fibroblasts
###end title 195
###begin p 196
(A) Northern blot of 20 mug total cellular RNA per lane extracted from control and fibroblasts stimulated with 0.4 mug/ml and 1 mug/ml osteopontin. Both concentrations of osteopontin induced an up-regulation in the expression of alpha1 type I collagen.
###end p 196
###begin p 197
(B) Western blot showing no effect of osteopontin on immunoreactive alpha smooth muscle actin. Recombinant TGF-beta1 was used as a positive control.
###end p 197
###begin p 198
C, control; OPN, osteopontin.
###end p 198
###begin title 199
Effect of Osteopontin on MMP-7 Gene and Protein Expression and Activity in A549 Epithelial Cells
###end title 199
###begin p 200
(A) Northern blot of 20 mug total cellular RNA per lane extracted from control and A549 cells stimulated with 0.4, 1, and 2 mug/ml osteopontin.
###end p 200
###begin p 201
(B) Densitometry of Northern blot and normalization of MMP-7 to 18S demonstrates a 3- to 4-fold increase in MMP-7 over control.
###end p 201
###begin p 202
###xml 77 78 77 78 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 115 116 111 112 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 120 121 113 114 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
(C) Real-time PCR showing up-regulation of MMP-7 expression by osteopontin (*p < 0.01) and inhibition by anti-alphavbeta3, anti-CD44, anti-EGFR, and GRGDS.
###end p 202
###begin p 203
(D) Western blot demonstrating an increase of immunoreactive MMP-7 in conditioned medium from A549 epithelial cells stimulated with osteopontin. Activation of pro-MMP-7 by APMA is shown in leftmost lane.
###end p 203
###begin p 204
###xml 65 71 <span type="species:ncbi:9913">bovine</span>
(E) Zymography of conditioned media in 12.5% SDS gels containing bovine CM-transferrin (0.3 mg/ml) and heparin as substrate.
###end p 204
###begin p 205
C, control; OPN, osteopontin.
###end p 205
###begin title 206
Osteopontin and MMP-7 Colocalization in IPF Lungs
###end title 206
###begin p 207
(A-C) MMP-7 staining is shown in green (A), osteopontin is shown as red staining (B), and overlap of staining is shown in yellow (C), suggest colocalization of MMP-7 and osteopontin in alveolar epithelial cells in IPF lungs (60x).
###end p 207
###begin p 208
(D) A lower-magnification image (20x) of the same region (A-C) with the same color coding. The white rectangle depicts area shown in (A-C).
###end p 208
###begin title 209
Weakest Link Models of Osteopontin and MMP-7
###end title 209
###begin p 210
IPF samples are depicted in solid dots and controls in open dots; the y-axis is MMP-7 expression and x-axis is osteopontin expression. Black solid line is the curve of optimal use showing that the expression levels for MMP-7 and osteopontin jointly interact to determine the IPF phenotype. The probability contour plot is shown in terms of the observed expression data (scale is log base 2 for gene expression data) (A); and probability contour plot is shown in terms of percentiles of the data (scale is percentiles) (B).
###end p 210
###begin title 211
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Characteristics
###end title 211
###begin title 212
Primers and Probes for Real-Time PCR
###end title 212
###begin p 213
###xml 129 134 <span type="species:ncbi:9606">human</span>
Citation: Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, et al. (2005) Up-Regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2(9): e251.
###end p 213

